List of Exforge Hct drug patents
Exforge Hct is owned by Novartis.
Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.
Exforge Hct has a total of 3 drug patents out of which 0 drug patents have expired.
Exforge Hct was authorised for market use on 30 April, 2009.
Exforge Hct is available in tablet;oral dosage forms.
The generics of Exforge Hct are possible to be released after 16 November, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(3 months from now) | |
| US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(3 months from now) | |
|
US8475839
(Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(9 months from now) | |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
EXFORGE HCT family patents
8
United States
4
China
3
Korea, Republic of
3
Japan
3
Peru
3
European Union
2
Hong Kong
2
Brazil
2
Australia
2
Mexico
2
Argentina
2
South Africa
2
Russia
2
Norway
2
Canada
2
New Zealand
2
Taiwan, Province of China
2
Ecuador
1
Austria
1
Morocco
1
Chile
1
Poland
1
Malaysia
1
Spain
1
Germany
1
Israel
1
Cyprus
1
Tunisia
1
Slovenia
1
Portugal
1
Egypt
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic